ME EIFE COEA



Maillanne Plantail No. 289

DE V.C. LONDON MANAGEMENT



MANIMALIAN TOXICOLOGY BRANCH DIVISION OF TOXICOLOGY

May 1988

Toxicology Series: 145

LETTERMAN ARMY INSTITUTE OF RESEARCH PRESIDIO OF SAN FRANCISCO, CALIFORNIA 94129 The last by solvental of Hydroxyures, a Positive Coppes et al

Secretaries, in this deposition in whole or in part is problemed except with the permission of the financial Acers institute of Research Presiding of San Prancisco, California 94129.

Regulated in Different Trade in Information Country is anthonized to reproduce the document for United San Companies.

Common with respect when it is no longer mental. Do not return to the originator.

STREET OF TRACE Selling in his report duck not constitute an official endorsoment or approval of the sec

in the first the resource described in this report, the investigation affected to the "Cuttle for the Concut and United Interesting Assembly," as promotipated by the Committee on Revision of the Guide for assembly Assembly Sections and Care, intelline of Laboratory Asimal Resources, National Resources (constituted)

This material has been reviewed by Letterman Army Institute of Research and there is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the author(s) and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defence. (AR 360-5)

(Signature and date)


This disconnect has been approved for public release and sale; its distribution is unlimited

REPORT D	OCUMENTATIO	N PAGE			Form Approved OMB No. 0704-0188
1a. REPORT SECURITY CLASSIFICATION UNCLASSIFIED		16. RESTRICTIVE	MARKINGS		
2a. SECURITY CLASSIFICATION AUTHORITY 2b. DECLASSIFICATION / DOWNGRADING SCHEDU	LE •	4		BEEN A	APPROVED FOR : ITS
		DISTRIBUT	ION IS UN	LIMIT	ED
4. PERFORMING ORGANIZATION REPORT NUMBE	R(S)	5. MONITORING	ORGANIZATION RE	PORT NU	MBER(S)
LAIR Institute Report No.					
6a. NAME OF PERFORMING ORGANIZATION Mammalian Toxicology Br.	6b. OFFICE SYMBOL (If applicable)	7a. NAME OF MC	ONITORING ORGA	VIZATION	
Division of Toxicology	SGRD-UL-TO-M				
6c ADDRESS (City, State, and ZIP Code) Letterman Army Institute Presidio of San Francisco 94		76. ADDRESS (City	y, State, and ZIP (iode)	
8a. NAME OF FUNDING/SPONSORING ORGANIZATION US Army Medical		9. PROCUREMENT	INSTRUMENT IDE	NTIFICATI	ON NUMBER
Research and Development C	Onditalia	10. SOURCE OF F	INDING MIMAGE		
8c ADDRESS (City, State, and ZIP Code) Ft. Detrick		PROGRAM	PROJECT	TASK	WORK UNIT
Frederick, MD 21701-5010		ELEMENT NO.	NO.	NO.	ACCESSION NO
·		62 720A	A835	AB	DA303913
11. TITLE (Include Security Classification) Developmental Toxicity Po Rabbits 12. PERSONAL AUTHOR(S)	tential of Hy	droxyurea,	a Positi	ve Cor	ntrol, in
Valerie G. Coppes, Charlo	tte L. Speckm	an, and Do	n W. Kort	e, Jr.	
13a. TYPE OF REPORT 13b. TIME CO Institute FROM 5/	OVERED 4/84 _{TO} 26/7/8	14. DATE OF REPOR		Day) 15.	PAGE COUNT 88
16. SUPPLEMENTARY NOTATION					
17. COSATI CODES	18. SUBJECT TERMS (C				
FIELD GROUP SUB-GROUP	⊳Developmenta Rabbit	l Toxicolo	gy, Terato	ology	Hydroxyurea
The developmental toxicity New Zealand White rabbits. Days 6 through 18 of gesta 200, 225, 300, and 450 mg/section on Day 29 and weig Bouin's solution for visce skeletal examination. Pregroups had 100% resorption 225, 300, and 450 mg/kg/da Zealand White rabbits. Mamg/kg/day groups were unde tonque, situs inversus of pairs of ribs, and extra v	potential of Hydroxyurea tion. Dose 1 kg/day. Fetu hed, examined ral examinati gnant females s. Hydroxyur y produced de lformations o rdevelopment the esophagus	hydroxyure was administed by tested seek were described by the seek were described by the seek welopmental courring in the hear and stomage	istered by ed were 0, elivered by, and producin red so, 300, an levels of toxic effect atria, eh, cervice	oral 25, 3 y cess cessed tain 3 d 450 50, 3 fects 150, 6 malforal ril	gavage on 50, 150, arean d in either for mg/kg/day 150, 200, in New and 200 rmed
20 DISTRIBUTION/AVAILABILITY OF ABSTRACT ☑ UNCLASSIFIED/UNLIMITED ☐ SAME AS R	PT DTIC USERS	21 ABSTRACT SEC UNCLASS	IFIED		
228. NAME OF RESPONSIBLE INDIVIDUAL		226 TELEPHONE (III 415 561-2		1	
MAJ Don W. Korte, Jr. DD Form 1473, JUN 86	Previous editions are o				D-UL-T LIION OF THIS PAGE

ABSTRACT

The developmental toxicity potential of hydroxyurea was tested in pregnant New Zealand White rabbits. Hydroxyurea was administered by oral gavage on Days 6 through 18 of gestation. Dose levels tested were 0, 25, 50, 150, 200, 225, 300, and 450 mg/kg/day. Fetuses were delivered by cesarean section on Day 29 and weighed, examined externally, and processed in either Bouin's solution for visceral examination or alizarin red stain for skeletal examination. Pregnant females in the 225, 300, and 450 mg/kg/day groups had 100% resorptions. Hydroxyurea at dose levels of 50, 150, 200, 225, 300, and 450 mg/kg/day produced developmental toxic effects in New Zealand White rabbits. Malformations occurring in the 50, 150, and 200 mg/kg/day groups were underdevelopment of the heart atria, malformed tongue, situs inversus of the esophagus and stomach, cervical ribs, 14 pairs of ribs, and extra vertebrae

Key Words: Developmental Toxicity, Teratology, Hydroxyurea, Rabbit



AND PROPERTY OF THE PROPERTY O

13.55.55

PREFACE

TYPE REPORT: Developmental Toxicity Study

TESTING FACILITY:

U.S. Army Medical Research and Development Command Letterman Army Institute of Research Presidio of San Francisco, CA 94129-6800

SPONSOR:

Companyor Response Consider Describer Correspond Consideration Profession Response Respondent Describer De

U.S. Army Medical Research and Development Command Letterman Army Institute of Research Presidio of San Francisco, CA 94129-6800

PROJECT: A835; Work Unit 180

Environmental Health Effects of Army Materials

STUDY NO.: 74021

STUDY DIRECTOR: Don W. Korte Jr, PhD, MAJ, MS

PRINCIPAL INVESTIGATOR: Valerie G. Coppes, BS

CO-PRINCIPAL INVESTIGATOR: Charlotte L. Speckman

REPORT AND DATA MANAGEMENT: A copy of the final report,

study protocol, addenda, retired SOPs, and raw data will be retained in the LAIR Archives. Alizarin specimens will be

retained in the LAIR Pathology

Archives.

TEST SUBSTANCE: Hydroxyurea

INCLUSIVE STUDY DATES: 5 Apr 84 - 26 July 84

OBJECTIVE: The objective of this study was to demonstrate the developmental toxicity of a positive control compound, hydroxyurea, in the New Zealand White rabbit in accordance with LAIR developmental toxicity test standard operating procedures.

ACKNOWLEDGMENTS

 $\ensuremath{\mathsf{SP5}}$ rusto Rodriguez, BS, and Richard Katona assisted with the animal care.

SIGNATURES OF PRINCIPAL SCIENTISTS INVOLVED IN THE STUDY

We, the undersigned, declare that Study 74021 was performed under our supervision, according to the procedures described herein, and that this report is an accurate record of the results obtained.

DON W. KORTE

MAJ, MS

Study Director

alerie & Coppes 25 May 88 LERIE G. COPPES / DATE

DAC

Principal Investigator

CHARLOTTE L. SPECKMAN / DATE

Co-Principal Investigator



DEPARTMENT OF THE ARMY

LETTERMAN ARMY INSTITUTE OF RESEARCH FRESIDIO OF SAN FRANCISCO, CALIFORNIA 94129-6800

REPLY TO

SGRD-ULZ-QA

10 May 1988

MEMORANDUM FOR RECORD

SUBJECT: Quality Assurance Audit of non-GLP Study 74021

The raw data for non-GLP Study 74021 and the institute report entitled "Developmental Toxicity Potential of Hydroxyurea, a Positive Control, in Rabbits," Toxicology Series 145, was audited on 11 April 1988 and was found to be accurate.

Caroy M Newio

CAROLYN M. LEWIS

Chief, Quality Assurance

TABLE OF CONTENTS

P	age
Abstract	i
Prefacei	lii
Acknowledgments	.iv
Signatures of Principal Scientists	v
Report of Quality Assurance Unit	
Table of Contents	
BODY OF REPORT	,
INTRODUCTION	1
Objective of the Study	1
MATERIALS	
Selection of the Positive Control Positive Control Substance Vehicle Animal Data Husbandry	1 2 2
METHODS	3
Acclimation. Group Assignment. Desage Levels/Administration. Compound Preparation. Breeding. Cesarean Section Procedure. Observations and Records. Schedule of Study Events. Statistical Analysis. Deviations from Original Protocol Raw Data and Final Report Storage.	3 3 4 4 4 4 5 5 5
RESULTS	
Maternal Data	7

PERSONAL DISLOSSE PROPER ASSESSE

14.1.1.1 20000000

able	of	Contents	3	(Continued)
D	ISCU	SSION		
C	ONCL	usion		
R	EFER	ENCES		
A	PPEN	DICES		
		Appendix Appendix Appendix Appendix Appendix Appendix Appendix Appendix Appendix	B C D E F G H I J	Chemical Data Animal Data Schedule of Study Events Individual Maternal Body Weights Individual Maternal Clinical Signs Individual Gestational Data Fetal Sex, Weight, and Length Fetal External Examination Fetal Visceral Examination Fetal Skeletal Examination Incidence of Fetal Examination Findings
O	FFIC	IAL DISTR	RIBU	JTION LIST

Developmental Toxicity Potential of Hydroxyurea, a Positive Control, in Rabbits -- Coppes et al

INTRODUCTION

The Toxicology Group, LAIR, has been tasked to perform toxicological evaluation of compounds to include developmental toxicity testing in two species, rat and rabbit. Developmental toxicity is the induction of adverse effects on the developing organism as a result of *in utero* exposure to an agent. The manifestations of developmental toxicity include death of the developing organism, structural abnormality (teratogenicity), altered growth, and functional deficiency. This report presents the results of a study to evaluate the developmental toxicity potential of a positive control, hydroxyurea, in rabbits.

ALLEGATED STATESTICS SECRETARIAN STATESTICS STATESTICS STATESTICS STATESTICS STATESTICS

Cbjective of the Study

The objective of this study was to demonstrate the developmental toxicity of a positive control compound, hydroxyurea, in the New Zealand White rabbit in accordance with LAIR developmental toxicity test standard operating procedures.

MATERIALS

Selection of the Positive Control

Hydroxyurea, a rapidly acting teratogen, is an inhibitor of DNA synthesis and a cytotoxic agent which selectively kills cells in the S-phase of the cell cycle (1).

Positive Control Substance

Chemical Name: Hydroxyurea

Chemical Abstract Service Registry No.: 127-07-1

Molecular Structure: Cli4 N2 O2

Molecular Weight: 76.06

Source: Sigma Chemical Company P.O. Box 14508
St. Louis, MO 63178

Additional information about the positive control appears in Appendix A.

Vehicle

The vehicle for hydroxyurea was sterile water for injection obtained from Cutter Laboratories, Inc, Emeryville, CA, and Abbott Laboratories, North Chicago, IL. Expiration dates were February 1985 and March 1986.

Animal Data

Thirty-two female and eight male New Zealand White rabbits were obtained from Elkhorn Rabbitry, Watsonville, CA. They were identified individually by ear tattoo numbers 34F237 through 84F268 for the females and 84F269 through 84F276 for the males. The weights of the females ranged from 3.28 to 4.47 kg, and the weights of the males ranged from 3.67 to 4.62 kg when released from quarantine. Additional animal data appear in Appendix B.

The rabbit has proven to be a sensitive test system for teratology studies (2). Historic data on malformations and variants in New Zealand White rabbits are well documented (3, 4).

Husbandry

Upon arrival at LAIR rabbits were quarantined for 14 cays. After release from quarantine rabbits were housed individually in stainless steel wire mesh cages in racks equipped with automatically flushing dump tanks. Bedding was not provided. Rabbits were fed Purina Rabbit Chow 5315

(Ralson Furina Company, St. Louis, MO). Nonpregnant rabbits were fed approximately 120 grams of chow per day, and pregnant rabbits were fed approximately 180 grams per day from 18 Apr 84 until 10 Jun 84. The feed was increased to approximately 180 grams per day for nonpregnant animals and approximately 240 grams per day for pregnant animals on 11 Jun 84. Water was provided by automatic water dispensers. The animal room temperature was maintained in a range between 17°C and 22°C with a relative humidity range between 42 and 76% with occasional spikes up to 98% during room cleaning. The photoperiod was 12 hours of light per day.

METHODS

Methods used are described in detail in LAIR "Teratology Testing Procedure" OP-STX-40 (5) and were in accordance with Environmental Protection Agency and Food and Drug Administration guidelines for developmental health effects (6,7).

Acclimation

en de la composición Esta de la composición de la composición

After release from quarantine, each female was predosed with water several times during a six day acclimation period. Animals were observed daily for signs of illness.

Group Assignment

Females were assigned to test groups according to OP-ISG-21 "Animal Randomization Procedure" on the Data General ECLIPSE C/330 computer (8). Sequences of numbers corresponding to the number of dose groups were generated. As females were bred, they were assigned to one of the dose groups.

Dosage Levels/Administration

The dosage levels of nydroxyurea tested were 0, 25, 50, 150, 200, 225, 300 and 450 mg/kg/day. Bred females were dosed daily from Day 6 through Day 18 of gestation. Day 0 was the day of breeding. The dosage was calculated on the Day 6 body weight and administered in a volume of 2 ml/kg body weight. Vehicle control animals received sterile water at a volume of 2 ml/kg body weight. Animals were dosed by oral intubation using a 10-cc syringe equipped with a 13-cm length of polyethylene tubing, inner diameter 1.67 mm, outer diameter 2.42 mm (Clay Adams, Parsippany, NJ). Bred females were dosed from 30 Apr 84 through 15 Jul 84.

Compound Preparation

Dosing solutions were prepared by mixing hydroxyurea in an appropriate volume of sterile water for injection. The preparations were heated slightly to attain complete dissolution and refrigerated. Before dosing the animals, the vials were warmed slightly to redissolve crystallized hydroxyurea.

Breeding

Each female was bred randomly to one or two males. Mating was confirmed by observation of the pair mating. The day of mating was designated as Day 0 of gestation. Females were bred from 24 Apr 84 through 27 Jun 84.

Cesarean Section Procedure

Dams were weighed and euthanized with CO₂ on Day 29 cf gestation. All females were examined, and nonpregnant ones were removed from the study. Gravid uteri were examined for number of implantation sites, resorptions, and live and dead fetuses. The uterus and ovaries were removed and the corpora lutea counted. The dams were examined for gross visceral signs of toxicity and reweighed. Each fetus was weighed, measured crown-to-rump, and examined externally. Fetuses were assigned alternately to either skeletal or visceral examination groups.

SENT EXERCISE TESTERISE FREGREET SENSONET BENEVENET FREGREES FONSSONET BENEVENET BENEVENET BENEVENET BENEVENET

Fetuses assigned for skeletal examination were placed in 70% ethanol and processed by the alizarin red S staining technique of Crary (9). After processing, the specimens were placed in glycerol with a few crystals of thymol to inhibit bacterial and mold growth. Fetuses assigned for visceral examination were placed in Bouin's solution. The body walls were pierced to allow penetration of the fixing solution.

Observations and Records

Bred females were weighed on Days 0, 6, 12, 18, 24, and 29 of gestation. Females were observed daily from Day 0 through Day 29 for clinical signs of toxicity, abortion, or premature delivery. Date, time, and amount of dosing solution administered were recorded during the daily dosing on Days 6 through 18. At cesarean section, body weight, sterine data, and results from gross examination of the dam sere recorded. The dams were reweighed after removal of the gravid uterus to obtain the Corrected Day 29 weight.

Fetal weight, crown-to-rump measurement, and external examination findings from live fetuses were recorded. Bouin's fetuses were examined under low magnification by the modified Wilson freehand razor blade sectioning technique (10). The skeletons stained by alizarin were examined under low magnification on a light box for degree of ossification, malformations, and alignment. The sternebrae, ribs, vertebrae, metacarpals, and metatarsals were counted.

Schedule of Study Events

The historical listing of study events is given in Appendix C.

Statistical Analysis

Means and standard deviations were performed on maternal weights, uterine, and litter data.

Deviations from Original Protocol

Females were bred by two males rather than one to increase pregnancy rate. The breeding period was extended from two weeks to two months, until all females were bred. The first litters were examined to determine whether adjustments in the dose levels were appropriate for the remaining females. The original protocol specif ed five dose groups: 0, 50, 150, 300, and 450 mg/kg/day hydroxyurea. On study Day 16 the first female assigned to the 450 mg/kg/day group died. Because the teratology testing procedure recommends less than 10% maternal deaths in the high dose group, it was determined that 450 mg/kg/day hydroxyurea administered on 13 consecutive days was too high (5). Two other females also assigned to this group were dosed with 450 mg/kg/day hydroxyurea on Days 6 through 10; then because of the death of the first female, the dosage was lowered on Day 11 to 300 mg/kg/day for the remainder of the dosing period. A lower dose group, 25 mg/kg/day hydroxyurea, was included in the study. A fourth female assigned to the 450 mg/kg/day dose group, but not yet dosed, was transferred to the 25 mg/kg/day dose group. After cesarean sectioning of the earliest bred animals, it was determined that intermediate doses between 150 mg/kg/day and 300 mg/kg/day were needed to demonstrate a dose-response relationship. Two new dose groups, 200 mg/kg/day and 225 mg/kg/day, were included in the study.

These adjustments to the original dose levels were necessary to prevent maternal deaths, to demonstrate a dose-related developmentally toxic effect, and to estimate the no-observed-effect level.

Raw Data and Final Report Storage

A copy of the final report, study protocol, addenda, raw data, and SOPs will be retained in the LAIR Archives. Alizarin specimens will be retained in LAIR Pathology Archives.

RESULTS

Maternal Data

The number of bred animals assigned to each group, number of animals that died, number of animals that were pregnant, and number of animals with live litters are presented in Table 1. There was no difference in percent of pregnant animals with live litters in the 0, 25, 50, 150, and 200 mg/kg/day hydroxyurea dose groups. The pregnant females in the 225, 300, and 450 mg/kg/day dose groups had no live litters.

One maternal death occurred on study Day 16 in the 450 mg/kg/day dose group. Necropsy findings reported the death was most likely caused by bacteremia/septicemia brought about by necrosis of small intestine mucosa. The necrosis may have been caused or aggravated by the test compound, hydroxyurea.

Individual maternal weights and weight changes are listed in Appendix D, and the group means are presented in Table 2. Slight weight loss occurred in most dose groups (not dose-related) during the study period (Corrected Day 29 weight - Day 0 weight). During the treatment period (Day 18 weight - Day 6 weight), weight gain occurred in all dose groups except that the animals assigned to the 450 mg/kg/day group, which had been dosed with 450 mg/kg/day from Days 6 through 10 and 300 mg/kg/day from Days 11 through 18, lost weight.

Individual maternal climical signs and necropsy findings are listed in Appendix E. Finical signs per group during pretreatment (Day 0 through Day 5), treatment (Day 6 through Lay 18), posttreatment (Day 19 through Day 28), and necropsy indings at cesarean section (Day 29) are found in Tables 3a, 1, c, and d, respectively. One female, 84F264 in the control croup, aborted on Day 22 and was euthanized on Day 29. Off

ONT BEREEZE VOUCKAT BOODDIN KKOKKAT TEKKKKAT PITTEEDIT BIKKKAN DOODDIN MAADIKIT KKKKKK

feed (animal did not eat approximately 1/4 or more of its daily feed ration) was the most frequent clinical sign during the pretreatment, treatment, and posttreatment periods and was not dose-related. Clinical signs that occurred more frequently in the 300 or 450 mg/kg/day dose groups during treatment and posttreatment were salivation; inactivity; alopecia; pallor of lips, nose, and gums; and death. At cesarean section, dark spots on ovaries was the only dose-related sign of maternal toxicity.

Cesarean/Fetal Data

The individual number of implantations, resorptions, percent resorptions, and number and percent of live and dead fetuses are listed in Appendix F. The summary by group is presented in Table 4. The 225, 300, and 450 mg/kg/day dose groups had lower implantation efficiencies and higher resorption rates than the control group. Hydroxyurea produced 100% resorptions in the three high dose groups and a dose-dependent increase in percentage of dead fetuses in the 50, 150, and 200 mg/kg/day groups. The individual fetal sex, weight, and crown-to-rump length are given in Appendix G. The group means are presented in Table 5. The fetuses in the 200 mg/kg/day group were lighter in weight and shorter in length than the controls or lower hydroxyurea groups.

Individual external examination findings are presented in Appendix H. A summary by dose group is in Table 6. External malformations and variants occurred in the 150 and 200 mg/kg/day dose groups.

Individual visceral examination findings are presented in Appendix I. A summary by dose group is in Table 7. Visceral variants were dose-related, ranging between 20% in the control group and 57% in the 200 mg/kg/day group, with the exception of 80% occurring in the 25 mg/kg/day dose group. Since the 80% represented only one litter, this is considered an aberration rather than dose-related. Visceral malformations occurring in the 50, 150, and 200 mg/kg/day dose groups were marked underdevelopment of heart atria, situs inversus of esophagus and stomach, ectopic kidney, and malformed tongue.

Individual skeletal examination findings are presented in Appendix J. A summary by dose group is provided in Table 8. Skeletal variants occurred in high frequency in all groups. Many fetuses had 13 pairs of ribs or a unilateral 13th rib. Split, unilaterally ossified, fused, scrambled, or diagonally shaped sternebrae occurred frequently in the 150 and 200 mg/kg/day dose groups. There were no differences in

PARTICIONAL PROPERTY PROPERTY OF PROPERTY FOR SOCIETA DESCRIPTION OF PROPERTY OF PROPERTY

the number of sternebrae, coccygeal vertebrae, metacarpals, metatarsals, and phalanges cssified between groups. Skeletal malformations were dose-related and were found in the 150 and 200 mg/kg/day dose groups. Twenty or 21 thoracic and lumbar vertebrae (19 is the normal number) occurred in 74% of the 150 mg/kg/day dose group and in 62% of the 200 mg/kg/day dose group fetuses. Rudimentary cervical rib occurred in 62% of the 200 mg/kg/day dose group fetuses compared to 4% (one fetus) in the control group. Eight cervical vertebrae (seven is the normal number) occurred in 26% of the 150 mg/kg/day fetuses and in 100% of the 200 mg/kg/day fetuses. Misaligned and fused coccygeal vertebral arches occurred in two fetuses in the 200 mg/kg/day dose group.

The individual incidence of external, visceral, and skeletal variations and malformations is found in Appendix K. A summary by dose group of the effect of hydroxyurea on the incidence of fetal malformations and variations is presented in Table 9. Variants occurred in all dose groups. Malformations were dose-related, increasing in frequency with increasing dose levels of hydroxyurea.

Table 1 Effect of Hydroxyurea on Survival and Pregnancy

			Hy	droxyur	Hydroxyurea (mg/kg/day)	kg/day)		
	0	25	50	150	200	225	300	450
Bred females	7	-	4	4	4	4	4	m
Number that died Percent that died	00	00	00	00	00	00	00	33
Number surviving to Day 29 Gravid	7 9	r-1 r-	4 r	4.4	40	4-	বাং	% C
Percent gravid With live litters	86.	100	75	100	50	25	100	100
Percent with live litters	83	100	100	100	100	0	00	0

then 300 mg/kg/day from *Dosed with 450 mg/kg/day hydroxyurea from Days 6 through 10, Days 11 through 18.

Effect of Hydroxyurea on Maternal Body Weights and Weight Changes* Table 2

KOASA MOSA ASSESSA WEGGEST MOSA WAS A SOCIOLO WAS A SOCIETA WAS A SOCIOLO WAS A SOCIETA WAS A SOCIAL WAS A

							Hydro	хуu	ırea	Hydroxyurea (mg/kg/day)	1/ dē	(Ā1					1
Day	0		25		50	}	7	150			200		225	300		450†	+
000004 000004 004444	988 198 198 198 198 198 198 198 198 198	388.	4 4 . 18 4 . 23 4 4 . 24 . 24 . 24 . 24	4.00	+1+1+1+1+1	220 220 220 199 24	3.7.69 9.00 4.00 88.00	+1+1+1+1+1	25 32 72 72 72	3.80 3.95 4.07 4.20	+1+1+1+1+1	. 22 . 28 . 29 . 33	3.91 3.99 4.06 4.20	3.83.3.83.3.7.8.4.4.4.4.4.4.4.4.4.4.4.4.4.4.4.4.4.4	. 12	3.97 4.02 3.89 3.59 4 3.77 4	.30 .31 .37
Gravid 29 4.0	35 +	.50	4.40	4.42	+1	. 28	4.16	+1	.32	4.31	+1	.21	4.18	3.76 ±	. 11	3.67 ±	.35
Correcte 29.	ed +	.38	3.83	3.87	+1	. 28	3.62	+1	.28	3.86	+i	19	4.14	3.73 +	60.	3.65 ±	.35
Weight Change Study PeriodS -0.07 ± .19 Treatment Per 0.11 ± .32	Chang Peri 07 ± ment 11 ±	9e 100 100 100 100 100 100 100 100 100 10	1§ -0.35 rriod« 32 0.16	-0.13	+1 +1	.05	0.21	+1 +1	.10	0.06	÷1 +1	.03	0.23	+ 0.09	.03	-0.17 ±	.01

The remaining 2 animals in this group were dosed 6 through 10, then 300 mg/kg/day from Days 11 *Mean ± S.D. in kg for pregnant females. ‡One animal in this group died on Day 16. with 450 mg/kg/day hydroxyurea from Days through 18.

Scroup mean of [Corrected Day 29 weight - Day 0 weight] «Group mean of [Day 18 weight - Day 6 weight].

PECCECCE PARTY

SASSACT DESTRUCT NOTATION PROSPERS

Kerinaa

Principal monagement from

KOSKI VIIIKKI DOODON DOOKKI DOOKKI BOOKSII KKKOOKI DOOKSII KOOKOOKI TOOKSOOTI TOOKSOOTI DOOKSOOKI BOOK

Table 3a Maternal Clinical Signs* - Pretreatment (Cays 0-5)

			Hydro	Hydroxyurea (mg/kg/day)	(/bw)	(g/day)		
	0	25	20	50 150 200 225	200	225	300	450
Number of animals observed Number with signs	9 7	10	r 0	4	7.7		4 -1	m 0
Abscess, dewclaws Off feed Brown material, perianal Yellow dried mucus around eyes Yellow-stained nose, forepaws	п п				нана	← 1	 1	

*Pregnant females.

Maternal Clinical Signs* - Treatment (Days 6-18) Table 3b

			Hydr	oxyure	(/bw) e	Hydroxyurea (mg/kg/day)		
	0	25	50	150	200	225	300	450
Number of animals observed Number with signs	99		mm	4.1	2 2	11	44	3+
Abscess, dewclaws Off feed Yellow-stained nose/mouth Yellow-stained paws	чъм	1	m H (3	нн	7	г ч	4 4	3+
Misdose Salivation Diarrhea Brown-stained perianal Soft feces	न नन		1 14	ч		,	7	255
Yellow-stained perianal Sound production Convulsion, tonic Tremors					ਜਿਜਜ	1	7	
Jepressed corneal reflex Dosing discontinued Inactive Pallor, lips/gums Jeath	1				H		Н	14 C F4

Pregnant females.

tiwo animals were dosed with 4tO mg/kg/day hydroxyurea from Day: 6 through 10, then 300 mg/tg/day from Days 11 through 18. Sine animal dosed with 450 mg/kg/day hydroxyurea from Days 6 through 11. Ammag/kg.lay hydroxyurea from Days 6 through 11. Ammag/kg.lay from Days 11 through 30.

MANGANNAT ESPANNAT ESPANNAT FREEZEAT NASSANAT NEGALAGAT RECECCES FORMANA TRES

	450÷	7, 73	Coppes et al	
	300	4. 4.	7 1 2	mg/kg/day
ys 19-28)	225	ਜਜ		300
<u> </u>	200	7.7	24 44	then
1 54	150	7	HQ 11 H	ngh iG,
3c osttreatment Hydroxyu	50	mm	H H N	6 through
Tuble 3c	25	F4 O	•	Days
Signs	0	S 6	המס ה ה ההה	yurea from
Maternal Clinical		Number of animals observed Number with signs	Abscess, dewclaws Off feed Yellow stained nose/mouth Nasal discharge, clear Nasal discharge, mucous Yellow-stained forepaws Rapid breathing Diarrhea Soft feces Aborted Bloody vaginal discharge Pallor, lips/rose/gums Hair pulling to make nest Alopecia, head Alopecia, head Alopecia, hind legs Hypertonia	SC

Table 3d Maternai Necropsy Findings* - At Cesarean Section (Day 29)

			7:					
		25	C)	03:	200	225	300	4501
Number of animals observed Number with signs	9	-1 .	mi	या	,7 ,7	F 1 1	4.4	2.2
aries ots on ovar ovaries	← (e ((7 et i	(7 +1	r·+	.d. 4.	(\)
ysts on fall luid in vagi orpora lutea liver torsion	~			ret		. ૧૯૦૧ ન ૧	H	г ч
Pale areas on liver Lungs pale, dark red spots Cysts on spleen Gali bladder enlarged, soft Gall bladder, off-white	, - -			ल्लंलन	c 1			

*Pregnant females. †Dosed with 450 mg/kg/day hydroxyurea from Days 6 through 10, then 300 mg/kg/day from Days 11 through 18.

Table 4

Effect of Hydroxyurea on Mean Gestational Data

			Hyd	Hydroxyurea (mg/kg/day)	a (mg/k	g/day)		
	0	25	50	150	200	225	300	450*
Number of corpora lutea	10.6	14	10.7	12.2	10.5	10	12.2	15.0
	0.6	12	5.7	10.2	0.6	4	7.5	10.0
Percent implantation efficiency:	83.2	86	7.06	83.2	86.0	40	60.7	67.0
	0.2		<u>ന</u> ഠ	0.8	0.5	4	7.5	10.0
Percent resorptions	4.0	∞	3.7	7.4	5.5	100	100.0	100.0
Number of fetuses								
Dead	0.2	0	0.3	0.8	1.0	0	0	0
Percent dead«	2.0	• ` >	6.0	6.9	11.0	0	0	0
Live fetuses	8.6	.⊣ .⊣	c.	8.8	7.5	0	0	0
Percent live≈	94.0	95	90.3	85.7	83.5	0	0	0

Dosed with 450 mg/kg/day hydroxyurea from Days & through 10, then 300 mg/kg/day from Days 11 through 18.

fGroup mean of [implantations per litter/corpora lutea per litter] X 100 «Group mean of [dead fetuses per litter/implantations per litter] X 100 ≈Group mean of [live fetuses per litter/implantations per litter] X 100 SGroup mean of [resorptions per litter/implantations per litter] X 100 «Group

Effect of Hydroxyurea on Litter Size, Sex, Weight, and Length* Table 5

		. 44	Hydroxyurea (mg	(mg/kg/day)	
	©	25	50	150	200
	.6 ++ 3.		.7 + 0.	+1 8.	.5 + 0.
	.4 + 3.		.0 + 1.	$.2 \pm 2.$.5+
E E E E E E E E E E E E E E E E E E E	$.2 \pm 1.$	•	.7 ± 1.	.5 + 1.	0 +1 0.
Percent males	$6.8 \pm 23.$	4.	4.3 ± 18 .	$6.5 \pm 17.$	9.8 + 3.
Body Weight (a)	8.9 ± 6.	5.	$0.9 \pm 4.$	$6.8 \pm 4.$	4.4 + 0.
Majes	8.9 + 5.	5.	$0.4 \pm 5.$	$6.2 \pm 3.$	$3.9 \pm 1.$
Females	38.5 ± 6.8	35.2	41.2 ± 4.3	36.8 ± 5.2	34.9 ± 0.4
Crown-rume length (mm)	4.3 ± 5.	φ,	$7.2 \pm 3.$	4.6 ± 5.	$2.0 \pm 1.$
	5.1 + 5.	ω,	7.1 ± 4.	3.5 ± 5.	1.5 + 3.
Fenales	$3.9 \pm 6.$	· (*)	$6.8 \pm 4.$	$5.2 \pm 6.$	$2.3 \pm 1.$

*Mean ± S.D. of litter means

Table 6

External Malformations and Variations in Fetuses of Hydroxyurea-treated Rabbits

		Hydrox	Hydroxyurea (mg/kg/day)	y/day)	
	0	25	50	150	200
Fetuses/litters	43/5	11/1	26/3	35/4	15/2
Variants Body dark red					1/1
Malformations Forepaw hyperflexed				1/1	
rail curiy Tongue malformed					2/11/1

A single fetus may have more than one abnormality and, therefore, would occur more than once in this table.

Table 7

Visceral Malformations and Variations in Fetuses of Hydroxyurea-treated Rabbits

		Hydro	Hydroxyurea (mg/kg/day)	g/day)	
	0	25	50	150	200
Fetuses/litters	20/5	5/1	12/3	16/4	7/2
Variants Nasal concha underdeveloped	1/1			3/2	3/2
;> (i)	T/T	1/1	1/1	1/1	
ਨਜ਼ਾਂ		1/1		1/1	
cle e small		1 / 1		27.1	1/1
Sall Diadder Small Kidnev small		1/1		1	
Xidney lobular Renal pelvis dilated	1/1		1/1	1/1	7/7
short/thick			1/1	1/1	
Malformations			,	,	
Heart atria under Meveloped			T / T	1/1	e / -
Social and Common Social Socia				1/1	,
Stomach simes and store of the Williams			-7/-1		7.7
/ · · · · · · · · · · · · · · · · · · ·					

A single ferus may have more than one ephormality and, therefore, once in this rebier.

Table 8

Skeletal Malformations and Variations in Fetuses of Hydroxyurea-treated Rabbits

		Hydroxyı	Hydroxyurea (mg/kg/day)	/day)	
	0	25	50	150	200
Fetuses/Litters	23/5	6/1	14/3	19/4	8/2
Variants					
Horns of hyoid not ossified Frontal/parietal suture jagged Bibs.				1/1	1/1
13 pairs	1875	5/1	11/2	7	(
Unilateral rudimentary 13th	4/3	7 / 6	C / 1-1	7/01	3/2
	3/3	1/1			
Short 1st				2/2	
Scapula spine crocked	1/1			1/1	
Sternebrae:					
Split/unilateral ossification Fused	2/1			4/3	1/1
Scrambled				2/2	1/1
Diagonal shape				7 / 7	1/1
Vertebral centrum split/malrotated					1/1
Sacral vertebral arch wide				1/1	i
Radius and ulna smail					1/1
Pubis incomplete essification					1/1

A single fetus may have more than one abnormality and, therefore, would occur more than once in this table.

Table 8 (Concluded)

Skeletal Malformations and Variations in Fetuses of Hydroxyurea-treated Rabbits

		Hydro	Hydroxyurea (mg/kg/day)	kg/day)	
	O	25	50	150	200
Fetuses/Litters	23/5	6/1	14/3	19/4	8/2
Malformations Ribs.					
	1/1			6/8	5/2
14 pairs Unilateral 14th				1/1	
Vertebrae: R cervical				5/1	8/2
20 thoracic + lumbar				13/4	5/2
<pre>21 thoracic + lumbar Scollosis</pre>				1/1	1/1
Coccygeal vertebrae misaligned/fused	fused,				2/1

A single fetus may have more than one abnormality and, therefore, would occur more than once in this table.

Table 9

Fetal Malformations and Variations Effect of Hydroxyurea on the Incidence of

		Hydroxyure	Hydroxyurea (mg/kg/day)	_	
	0	25	50	150	200
Number fetuses/litters 43	43/5	11/1	26/3	35/4	15/2
Any (External/Visceral/Skeletal) Malformations Variations	1/1 26/5	6/0 9/1	2/1	18/4 21/4	11.2
External examination Malformations Variations	0/0 0/0	0/0	0/0	1/1	3/2
Visceral examination Number fetuses/litters 20 Malformations Variations	20/5 0/0 4/3	5/1 0/0 4/1	12/3 2/1 3/3	16/4 2/2 6/2	755
Skeletal examination Number fetuses/litters Malformations Variations	23/5 1/1 22/5	6/1 0/0 5/1	14/3 0/0 14/3	19/4 16/4 15/4	8/28/2

DISCUSSION

Developmental toxicity is the induction of agreese effects on the developing organism as a result of in utero exposure to an agent. The manifestations of developmental toxicity include death of the developing organism, structural abnormality (teratogenicity), altered growth, and functional deficiency. The no-observed-effect level is the maximum concentration in a test which produces no observed adverse effects (6).

In this study, death of the developing organism was dose-related. The 225, 300, and 450 mg/kg/day dose groups had 100% resorptions (no live or dead fetuses), and the percent dead fetuses ranged from 2% in the control to 11% in the 200 mg/kg/day dose groups. External, visceral, and skeletal malformations were dose-related and occurred in the 50, 150, and 200 mg/kg/day dose groups. There were no malformations in the 25 mg/kg/day dose group. The presence of supernumerary 13th ribs at the thoracolumbar border is one of the most common variants in rabbits. The presence of a cervical rib is quite common in mice, but is a relatively rare anomaly in rabbits (4). The spontaneous occurrence ci supernumerary lumbar ribs is highly variable and determined by both genetic and extragenetic factors which influence the differentiation and growth of rib precursors at a specific stage of embryogenesis. The presence of extra vertebrae is much less common. Chemical agents, maternal stress, and embryo-toxicity attributed to maternal treatment have been associated with extra ribs (11). In this study, having 13 pairs of ribs, rather than the normal 12, was considered a variant, but 14 pairs of ribs, cervical ribs, and eight cervical or more than 19 thoracic + lumbar vertebrae were considered malformations. With the exception of one control fetus with a cervical rib, these malformations occurred only in the 150 and 200 mg/kg/day dose groups. Morphological changes such as these are interpreted with caution, and the test substance is considered a developmental hazard only when morphological changes occur in conjunction with other observations such as increased fetal loss (3). While increased numbers of vertebrae, 14 pairs of ribs, situs inversus of esophagus and stomach, and malformed tongue generally are not incompatible with life, they are permanent structural deviations from normal. Severely underdeveloped heart atria, which occurred in the 50 and 150 mg/kg/day dose groups, may be incompatible with or severely detrimental to normal postnatal survival. One fetus in the 150 mg/kg/day dose group had a hyperflexed forepaw. Since skeletal examination of this fetus revealed no abnormalities, the flexure may have disappeared with postnatal exercise and was not considered a skeletal malformation.

POSTATION ASSASSAS PERCESSAS RESESSAS

Although the dose level and time of administration were different, some of the findings in this study, such as high resorption rates, ectopic kidneys, stunted tails, and abnormal vertebrae, have also been reported in New Zealand White rabbits injected s.c. on Day 12 of gestation with 750 mg/kg hydroxyurea (12). The data support a dose-response increase in developmental toxicity with the positive control, hydroxyurea.

CONCLUSION

persingential vercecció (presente popularia de compania de compania de casa de compania de cesado de presentado

When given in oral doses of 50, 150, 200, 225, 300, and 450 mg/kg/day from Days 6 through 18 of gestation, the positive control substance, hydroxyurea, produced developmental toxic effects in New Zealand White rabbits. The LAIR developmental toxicity testing procedure for New Zealand White rabbits is a valid model for testing substances for developmental toxicity.

REFERENCES

- 1. DeSesso JM. Amelioration of teratogenesis. I. Modification of hydroxyurea-induced teratogenesis by the antioxidant propyl gallate. Teratology 1981;24:19-35.
- 2. Gibson JP, Staples RE, Newberne JW. Use of the rabbit in teratogenicity studies. Toxicol Appl Pharmacol 1966;9:398-408.
- 3. Palmer AK. Spontaneous malformations of the New Zealand White rabbit: The background to safety evaluation tests. Lab Anim 1968;2:195-206.
- 4. Palmer AK. Sporadic malformations in laboratory animals and their influence on drug testing. Adv Exp Med Biol 1972;27:45-60.
- 5. Teratology Testing Procedure. Standard Operating Procedure OP-STX-40. Presidio of San Francisco, CA: Letterman Army Institute of Research, 20 Oct 1981.
- 6. Office of Pesticides and Toxic Substances.

 Developmental Toxicity Study. Washington, D.C.: United States Environmental Protection Agency, 1984. (HG-Organ/Tissue-Den Tox).
- 7. Food and Drug Administration. Guidelines for reproduction studies for safety evaluation of drugs for human use. Washington, D.C.: Food and Drug Administration, 1966.
- 8. Animal Randomization Procedure. Standard Operating Procedure OP-ISG-21. Presidio of San Francisco, CA: Letterman Army Institute of Research, 9 Dec 1980.
- 9. Crary DD. Modified benzyl alcohol clearing of alicarinstained specimens without loss of flexibility. Stain Technol. 1962;37:124-5.
- 10. Wilson JG. Methods for administering agents and detecting malformations in experimental animals. In: Wilson JG, Warkany J, eds. Teratology: Principles and Techniques. Chicago: University of Chicago Press, 1965:267-77.
- 11. Khera KS. Common fetal aberrations and their teratologic significance: A review. Fundam Appl Tempol 1981;1:13-8.
- .2. DeSesso JM, Jordan RL. Drug-induced limb dysplasias in fetal rabbits. Teratology 1977;15:199-212.

Appendix A Chemical Data
Appendix B Animal Data
Appendix C Schedule of Study Events
Appendix D Individual Maternal Body Weights
Appendix E Individual Maternal Clinical Signs
Appendix F Individual Gestational Data
Appendix G Fetal Sex, Weight, and Length
Appendix H Fetal External Examination
Appendix I Fetal Visceral Examination
Appendix J Fetal Skeletal Examination
Appendix K Incidence of Fetal Examination Findings

APPENDICES

RECORD PROPERTY OF SERVICES AND PROPERTY AND PROPERTY OF THE P

Chemical Data

Chemical name: Hydroxyurea; Hydroxycarbamide; Hydrea;

Litalir

Chemical Abstract Service Registry No.: 127-07-1

Structural formula:

Molecular formula: CH4N2O2

Molecular weight: 76.06

The second in th

Source: Sigma Chemical Company

P.O. Box 14508

St. Louis, MO 63178

Lot No.Date of dosing solution preparation73F-064330 Apr 84, 4 May 8473F-037510 May 84, 21 May 84, 14 Jun 84103F-014025 Jun 84, 28 Jun 84, 7 Jul 84

Solubility: Freely soluble in water, hot alcohol*.

^{*} Windholz M, ed. The Merck Index. Tenth Edition. Rahway, NJ: Merck and Co., 1983:4772.

Animal Data

Species: Rabbit

Strain: New Zealand White (albino)

Source: Elkhorn Rabbitry

5265 Starr Way Watsonville, CA

Sex: 32 Females and 8 Males

Age:

Male: Age unknown, adult, proven breeders.

Female: Approximately 5 months, nulliparous.

Condition of animals at start of study: Normal

Body weight range of females at dosing: 3.39 - 4.61 kg

Schedule of Study Events

Date	Event
17 Feb 84	Date protocol approved.
5 Apr 84	Rabbits arrived at LAIR.
18 Apr 84	Rabbits released from quarantine.
19-23 Apr 84	Rabbits predosed with water.
23 Apr-27 Jun 84	Several female rabbits bred per day.
30 Apr-15 Jul 84	Bred females dosed.
23 May-26 Jul 84	Cesarean sections.

i i

Maternal			Day	Day of Gestation	ation			Weight	Charige
ID	0	9	77	7C)	24	Gravid 29	Corrected 29	29C-0†	18-6§
84F238	3.63	3.81	3.91	4.00	4.07	4.25	3.74	0.11	0.19
(84E243)	(4.13)	(3.96)	(3.95)	(4.01)	(4.13)	(4.14)	(4.12)	(-0.01)	(0.05)
84F246	3.67	3.86	3.90	5.03	4.27	4.36	3.78	0.11	0.17
84F251	4.66	4.57	4.73	4.86	4.86	4.76	4.48	-0.18	0.29
84F258	3.59	3.81	3.84		4.09	4.17	& %	60.0	0.30
94F260	4.51	4.60	4.69	٠ ٠ ٠	4.90	4.99	4.32	-0.19	0.25
34F264	3.84	3.91	4.00	3.37	3,38	3.55	3.53	-0.31	-0.54

*Meights in kg. Parentheses indicate that animal was not pregnant at cesarean section. Structly period (Day 29 Corrected - Day (). Streatment period (Day 18 - Day 6).

- 25 gm/kg/day Hydroxyurea Animals Individual Maternal Body Weights*

		!	Бау	Day of Gestation	ation			Weight Change	Change
Maternal ID	0	9	12	8 1	24	Gravid 29	Corrected 29	29C-0+	18-65
84F266	4.18	4.08	4.08 4.23 4.24 4.37 4.40	4.24	4.37	4.40	3.83	-0.35	0

*Weights in kg. †Study period (Day 29 Corrected - Day 0). \$Treatment period (Day 18 - Day 6).

- 50 mg/kg/day Hydrcxyurea Animals Individual Maternal Body Weights*

			Day	Day of Gestation	ation			Weight Change	Change
Maternai ID	٠.٠	9	12	æ • •	24	Gravid 29	Corrected 29	29C-01	(2) (0) (1) (1)
84F244	3.73	4.00	3.97	4.07	4.13 4.11	4.11	3.56	-0.18	.0.5
(84F249)	(3.81)	(3.80)	(3.87)	(3.93) (4.05) (3.99)	(4.05)	(3.99)	(3.96)	(0.15)	((::3)
84F253	. c2	4.10	4.11«	4.26	4.38	4.49	3.93	60.0-	
34F261	4.25	4.38	4.40	4.45	4.60	4.66	ক ক গো	-6.13	

*Weights in kg. Parentheses indicate that animal was not pregnant at cesarean section. 1Study period (Lay 29 Corrected - Day 0). Streatment period (Day 18 - Day 6). **Weighed on Day 13.

Individual Maternal Body Weights* - 150 mg/kg/day Hydroxyurea Animals

			Day	Day of Gestation	ation			Weight Change	Change
Maternal ID	0	Ų)	12	18	24	Gravid 29	Corrected 23	29C-0†	18-65
84F255	3.58	3.83	3.79	3.94	4.01	4.24	3.65	0.07	0.11
84F289	3.56	3.39	3.75	3.90	3.97	3.96	3.41	-0.15	0.51
हे असम् इ.स. १८५३	4.06	4.16	4.31	4.40	4.47	4.57	4.00	90.0-	0.24
C0744	5.56	3.77	3.67	3.77	3.85	3.85	3.42	-0.34	O

*Weights in kg. †Study period (Day 29 Corrected - Day 0). §Treatment period (Day 18 - Day 6).

Individual Maternal Body Weights* - 200 mg/kg/day Hydroxyurea Animals

			Day	Day of Gestation	ation			Weight Change	Change
Maternal ID	0	Q	12	18	24	Gravid 29	Corrected 29	29C-0†	18-6§
(84F245)	(3.84)	(4.16)	(4.16) (4.16)	1	(4.11) (4.22) (4.24)	(4.24)	(4.23)	(0.39)	(0.05)
84F250	3.64	ω 	3.86«	3.97	4.02	4.16	3.72	0.08	0.22
(84F252)	(4.09)	(4.42)	(4.42)	(4.34)	(4.29)	(4.39)	(4.36)	(0.27)	(-0.08)
84F254	3.95	4	4.27	4.43	4.32	4.45	3.99	0.04	0.28

Parentheses indicate that animals were not pregnant at cesarean section. by $29 \, \text{Corrected} - \text{Day} \, 0)$. tStudy period (Day 29 Corrected - Day Streatment period (Day 18 - Day 6). *Weights in kg.

«Weighed on Day 11.

KIND LILLIAM DITUIN MILLIAM SINSING SESSION SESSION BESSESSE DILLIAM BASSING BASSING SINDIAM

Individual Maternal Body Weights* - 225 mg/kg/day Hydroxyurea Animals

			Day	Day of Gestation	ation			Weight Change	Change
Maternal ID	0	Q	12	18	24	Gravid 29	Corrected 29	29C-0†	18-65
(84F240)	(3.63)	(3.98)	(3.97)	(3.89)	(3.99)	(4.11)	(4.09)	(0.45)	(-0.09)
(84F241)	(3.95)	(3.96)	(4.06)	(4.11)	(4.16)	(4.16)	(4.14)	(0.18)	(0.15)
845256	3.91	3.99	4.06	4.20	4.16	4.18	4.14	0.23	0.21
(84F265)	(4.27)	(4.61)	(4.54)	(4.64)	(4.57)	(4.63)	(4.61)	(0.34)	(0.03)

*Weights in kg. Parentheses indicate that animals were not pregnant at cesarean section. +Study period (Day 29 Corrected - Day 0). \$Treatment period (Day 18 - Day 6).

1811111 X555 X92

Individual Maternal Body Weights* - 300 mg/kg/day Hydroxyurea Animals

			Day	Day of Gestation	ation			Weight Change	Change
Maternal ID	0	9	12	1.8	24	Gravid 29	Corrected 29	29C-0†	18-6\$
84F239	3.75	3.93	3.77	3.87	7.79	3.68	3.68	-0.07	90.0-
84F248	3.92	4.02«	3.92	3.87	3.88	3.92	3.85	90.0-	-0.15
84F262	3.77	3.71	3.71	3.61	3.62	3.68	3.66	-0.11	-0.10
845268	3.86	3.67	3.95	3.76	3.76	3.76	3.74	-0.12	06.0

*Weights in kg. †Study period (Day 29 Corrected - Day 0). \$Treatment period (Day 18 - Day 6). *Weighed on Day 13.

Individual Maternal Body Weights* - 450 mg/kg/day Hydroxyurea Animals

			Day	Day of Gestation	itton			Weight Change	Change
Maternal ID	0	9	2	18	24	Gravid 29	Corrected 29	29C-0†	18-64.
84F242«	3.57	3.66	3.56	3.32	3.46	3.42	3.40	-0.17	-0.34
84E247	4.11	4.21	4.08≈						
84F257«	4.06	4.19	4.02	3.85	4.07	3.91	3.89	-0.17	-0.34

tStudy period (Day 29 Corrected - Day 0). STreatment period (Day 18 - Day 6). «Dosed with 450 mg/kg/aay from Days 6 through 10, then 300 mg/kg/day from Days 11 through 18 ≈Weighed on Day 13. Animal died Day 16. *Weights in kg.

Individual Maternal Clinical Signs - Control Animals

Maternal ID	Stucy Day(s)	Date(s)	Signs
84 F 238	0 - 28 7 - 22 27 - 29 19 - 21 20 - 22 27	27 Jun - 26 Jul 84 4 - 19 Jul 84 24 - 26 Jul 84 16 - 18 Jul 84 17 - 19 Jul 84 24 Jul 84 26 Jul 84	Abscess both dewclaws, cleaned daily with hydrogen peroxide and Betadine. Yellow stained nose Yellow stained nose Off feed Rapid breathing Rapid breathing At cesarean section, cysts on fallopian tubes.
84F246	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	25 - 29 Jun 84 2 - 3 Jul 84 9 - 12 Jul 84 16 - 20 Jul 84 23 Jul 84	Off feed Off feed Off feed Off feed
845251	14	14 May 84	Off feed
84F258	7 18 21 - 22	10 May 84 21 May 84 24 - 25 May 84	Possible misdose, white liquid from nose after dosing. Off feed Yellow stained nose, mouth

Individual Maternal Clinical Signs - Control Animals (Concluded)

Maternal ID	Study Day(s)	Date(s)	Signs
84F260	14 17 - 18 20 23 27 28	30 Apr 84 8 May 84 11 May 84 17 May 84 21 May 84 22 May 84	Off feed Off feed Yellow stained nose Yellow stained nose Soft feces Yellow stained nose
84F264	23 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -	21 - 23 May 84 22 - 25 May 84 23 May 84 24 May 84 25 May - 1 Jun 84 26 - 27 May 84 31 May 84 31 May 84 3 Jun 84 5 Jun 84 5 Jun 84 5 Jun 84 5 Jun 84	Soft feces Off feed Brown stained perianal Yellow stained mouth Inactive Off feed Soft feces Yellow stained nose; nasal discharge, mucus Aborted, 4 fetuses (1x2 cm) found under cage, bloody vaginal discharge Nasal discharge, mucus Yellow stained nose Off feed At cesarea: section, right ovary had a dark spot; cysts on fallopian tubes; gall bladder, off-white

Individual Materral Clinical Signs - 25 mg/kg/day Hydroxyurea Animals

POTON STATES STATES

Individual Maternal Clinical Signs - 50 mg/kg/day Hydroxyurea Animals

Maternal ID	Study Day(s)	Date(s)	Signs
84F244	18 20 - 21 29	21 May 84 23 May 84 1 Jun 84	Off feed Yellow stained forepaws At cesarean section, dark spots on ovaries
84F253	6 9 21 - 22 72	36 Apr 84 3 May 84 15 - 16 Zay 84 21 May 84	Off feed Misdose, appreximately 1/2 dos.ng solution spit out Off feed Off feed
84E261	22 - 1 - 1 - 2 - 2 - 1 - 2 - 2 - 2 - 2 -	16 - 17 May 84 22 - 23 May 84 24 - 25 May 84 24 - 25 May 84 31 May - 2 Jun 84 4 - 6 Jun 84	Yellow stained nose Off feed Yellow stained nose Off feed Yellow stained nose, forepaws Yellow stained nose, forepaws Yellow stained nose, forepaws

ID Day(s)		
84F255 26 - 28 28 29	21 May 8 21 - 23 May 8 23 May 8 24 May 8	84 Soft feces 84 Yellow stained nose 84 Alopecia, hindleg 84 At cesarean section, gall bladder enlarged, soft; dark spots cn ovaries
84F259 29	29 May 8	84 At cesarean section, pale areas on liver
84F263 29	7 Jun 6	84 At cesarean section, cysts on fallopian tubes and ovaries; cysts on spleen
84F267 6 - 8 8 - 9 12 14		84 Diarrhea 84 Yellow stained nose 84 Off feed 84 Yellow stained nose
20 - 23 20 - 23 24 - 25	May May	Off feed Off feed
, , ,	, - 20 May 30 May 1 Jun	of relicw scalled mose, lorepaws Off feed Control of the section of the sports on the section of the sports on the section of the sports on the sports of

Individual Maternal Clinical Signs - 200 mg/kg/day Hydroxyurea Animals

gyrni vecessei verranni vececed vanamen estatez editetti vecesse estatez incesse estatez.

Maternal ID	Study Day(s)	Date(s)	Signs
84F250		1 - 12 Jun 0 - 22 Jun	Yellow dried mucus around eyes; brown stain perianal; yellow stained nose, forepaws.
	14 - 18 20 - 22 28 29	25 - 29 Jun 84 1 - 3 Jul 84 9 Jul 84 10 Jul 84	Off feed Off feed Off feed At cesarean section, dark spots on ovary
84F254	5 - 9 12 - 13 14	25 - 29 Jun 84 2 - 3 Jul 84 4 Jul 84	neck for do tonic convu conds, then utes, depre onvulsions
	19 - 22 - 20 - 20 - 20 - 20 - 20 - 20 - 2	22 July 8 Lub 8 Lub 8 Lub 8 Lub 8	tremors; then appeared to be normal. Rabbit was returned to cage for 10 minutes; then was dosed. Off feed Yellow stained nose
	22 - 26 - 28 - 28 - 29	12 - 16 Jul 84 16 - 18 Jul 84 19 Jul 64	Soft feces Off feed At cesarean section, dark spots on ovaries; cysts on ovaries; lungs pale with dark red spots.

225 mg/kg/day Hydroxyurea Animals Individual Maternal Clinical Signs

manages of the second dispersion of the second the second of the second

Maternal	Study		
ID	Day (s)	Date(s)	Signs
84F256	14 - 17 18 - 22 21 - 25 22 - 25 29	28 Jun 84 2 Jul 84 9 - 12 Jul 84 13 - 17 Jul 84 16 - 20 Jul 84 24 Jul 84 24 Jul 84	Off feed Off feed Off feed Soft feces Soft feces Off feed Rabbit pulling out hair to make nest At cesarear section, mammary development; uterus enlarged and vascular as in pregnancy; cysts on fallopian tubes; uterus had 4 areas which appeared to be attachment sites for fetuses; dark spots on ovaries; fluid in vagina; corpora lutea, small, hard, red.

300 mg/kg/day Hydroxyurea Animals undividua Maternai Clinical Signs

RECOMPOSITION FOR THE PROPERTY OF THE PROPERTY

Macernal	Study Day(s)	Date(s)	Signs
\$\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	14 18 20 - 21 29	17 May 84 21 May 84 23 - 24 May 84 1 Jun 84	Off feed Off feed Off feed At cesarean section, ovaries small, dark spots
ση · μ· · · · · · · · · · · · · · · · · ·	27 28 11 16 27 28 28 28 28 28 28 28 28 28 28 28 28 28	30 Apr 84 2 - 4 May 84 4 May 84 6 - 10 May 84 10 - 16 May 84 14 - 22 May 84 21 - 22 May 84 21 - 22 May 84 22 - 23 May 84	Off feed Off feed Yellow stained mouth Off feed Salivation Palior lips, gums Off feed Nasal discharge, clear Nasal discharge, clear At cermean section, dark spots on ovaries
84F.72	8 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	8 - 25 May 84 27 May 64 29 May 84	Off feed Soft feces At desarean section, dark spots on ovaries
	1	20 - 13 May 84 21 - 26 May 84 24 May 84 27 Y - 1 PM 84 7 Jun 84	Off feed Off feed Yellow ctained periona. Off feed Paler lips, nose At cesarean section, dara pots on Overtor cysts on factors. Fulcs

Individuai Maternai Clinical Signs - 450 mg/kg/day Hydroxyurea Animals

Maternal ID	Study Day(s)	Date(s)	Signs
84F242*	13 - 18 15 20 - 21 21 26 - 29 26 - 29	14 - 19 May 84 16 May 84 17 May 84 21 - 22 May 84 22 May 84 25 May 84 27 - 30 May 84 30 May 84	Off feed Inactive; salivation Dosing discontinued due to weight loss Rabbit pulling out hair to make nest Hypertonia Alopecia, head Alopecia, head At cesarean section, dark spots on ovaries; liver torsion
9 6 6 7	8 14 15 15 16	2 May 84 8 May 84 6 - 9 May 84 9 May 84 9 May 84	Off feed Off feed Salivation Inactive; diarrhea Death
845255¥	11 13 - 18 20 - 24 29	12 May 84 14 - 19 May 84 11 - 25 May 84 20 May 84	Yellow stained mouth Off feed Off feed At sacrifice, dark spots on ovaries

6 through 10, then 300 mg/kg/day from *T. rej with 450 mg/kg/day rydroxyurea from Days iegs 11 through 18.

Individual Gestational Data - Control Animals

gestel upprazzabil upprazzesti doutrazzi u becooper upprazze

						Nu	Number of Fetuses	Fetuse	S
Maternal ID	Corpora Lutea	Implants	\$ Implants*	Resorptions	Resorptions+	Dead	ه Dead Deads	Live	% Live«
845238	<u>ដ</u>	10	91	0	O	1	10	თ	06
84F245	C) H	S	06	0	0	0	0	σ	100
84F251	∞	S	62	7	20	0	0	4	80
\$ \$ 1 1 2 2 2 2 2 3 2 3 3 3 3 3 3 3 3 3 3 3	, - 1	ω	73	0	0	0	0	900	100
845260	en H	೮ರ	100	0	0	0	0	<u>ب</u>	100

*[implintations per litter/corpora lutea per litter] x 100 t[rescriptions per litter/implantations per litter] x 100 (dead fetuses per litter/implantations per litter] x 100 w[live fetuses per litter/implantations per litter] x 100

proceeding leavesters

Individual Gestational Data - 25 mg/kg/day Hydroxyurea Animals

PRODUCTION TO SERVICE ACCOUNTS TO SERVICE ACCOUNTS

						Number of Fetures	f Fettit	
Material of the state of the st	00 00 00 00 00 00 00 00 00 00 00 00 00	ी कर्म किस्स किस्स	Implanto	Resorptions	% Resorptions Resorptionst	Dead Dead% Live		Livea
84776	<# ,-4	7.7	986	prod.	З	O		. J . T.
			,					

*[implantations per litter/conform lutes fer litter] x 100 t[resorptions per litter/implantations per litter] x 100 \$[dead feruses per litter/implantations per litter] x 100 *[live feruses per litter/implantations per litter] x 100 *[live feruses per litter/implantations per litter] x 100

Individual Gestational Data - 50 mg/kg/day Hydroxyurea Animals

Number of Fetuses	پ ts Implants* Resorptions Resorptions† Dead Deady Live Live«	90 1 11 0 0 8 89 82 6 0 0 0 9 100 100 0 0 9 82
	ب Implants Implant	9 90 9 82 11 100
	Corpora Lutea I	10 11
	Maternal ID	84524 84523 846261

*[implantations per litter/corpora lutea per litter] x 100 *[rescriptions per litter/implantations per litter] x 100 %[dead fetuses per litter/implantations per litter] x 100 %[live fetuses per litter/implantations per litter] x 100

APP INDIX F - 4

Individual Gestational Data - 150 mg/kg/day Hydroxyurea Animals

Materna: ID	Corpora Lutea	Implants	² Implants*	Resorptions	Resorptions†	Dead) Deads	Live	, Live«
84F255	ල ජ	r=4 r=4	85	, -1	6	0	0	0.1	91
84F259	₹ 7	13	93	г	ထ	(1)	15	0.7	77
84F263	ιŢ	(T)	82	0	O	0	0	S	100
84F267	11	ω	73	,4	13	,	13	y	75

*[implantations per litter/corpora lutea per litter] x 100 f(resorptions per litter/implantations per litter! x 100 %[dead fetuses per litter/implantations per litter] x 100 %[live fetuses per litter/implantations per litter] x 100

Individual Gestational Data - 200 mg/kg/day Hydroxyurea Animals

1		
S 0	% Live«	98 7.8
Fetus	Live	80 L
Number of Fetuses	% Deads	22
N	Dead	0 7
	% % Resorptions† Dead Dead§ Live Live«	11 0
	Resorptions	10
	tmplants Implants*	85 80
	Implants	თთ
	Corpora Lutea	11
	Maternai ID	84F250 84F254

*[implantations per litter/corpora lutea per litter] x 100 t[resorptions per litter/implantations per litter] x 100 %[dead fetuses per litter/implantations per litter] x 100 %[live fetuses per litter/implantations per litter] x 100

Individual Gestational Data - 225 mg/kg/day Hydroxyurea Animals

						NuN	Number of Fetuses	หลา เล	ທຸ
Materna: ID	Corpora Lutea	Implants	; mplants Implants*		% Resorptions Resorptions†	Dead	Deads	Live	Dead Deads Live Live«
9 14 7 14 14	C	٠,٣	40	4	100	0	O	0	0

*[implantations per litter/corpora lutea per litter] x 100 *[rescrptions per litter/implantations per litter] x 100 \$[dead fetuses per litter/implantations per litter] x 100 *[live fetuses per litter/implantations per litter] x 100

Individual Gestational Data - 300 mg/kg/day Hydroxyurea Animals

									?
Maternal ID	Corpora Lutea	Implants	₹ Implants*		% Resorptions Resorptionst		} Dead Dead\$ Live	Live	a Live«
84F239	თ	5	56	2	100	0	0	0	0
84F248	12	10	83	10	100	0	0	0	0
84F262	12	S	42	5	100	0	ပ	0	0
845269	16	10	62	10	100	0	0	0	0

*[implantations per litter/corpora lutea per litter] x 100 t[resorptions per litter/implantations per litter] x 100 \$[dead fetuses per litter/implantations per litter] x 100 %[live fetuses per litter/implantations per litter] x 100

Individual Gestational Data - 450 mg/kj/day~ Hydroxyurea Animals

						3	Number to recurses	n constant	Ž.
Macernal ID	Corpora Lutea	Implants	TMplants*	Resorptions	? Resorptions Resorptions†) Dead Dead: Live	Live	Live«
84F242	18	12	6	12	100	0	0	0	0
(A)	1.2	cυ	<u>(, , , , , , , , , , , , , , , , , , , </u>	သ	100	0	0	0	0

or ore and the per litter/company of through 10, then 300 mg/kg/day from Days 11 through 18. Alimpiantation per litter/company lutes per litter! x 100 %[dead fetuses per litter/implantations per litter] x 100
«[live fetuses per litter/implantations per litter] x 100 *(rescriptions per litter/implantations per litter) x 100

STATE OF THE PARTY OF THE PARTY

ESSERVE HODINE

Printeral 98899022 Vectored

20020021 SSSSSS

Fetal Sex, Weight, and Length - Control Animals

		Sex		Mean	Mean Weight (g) ± S.D.	+ S.D.	Mean	Mean Length (mm) ± S.D.	± S.D.
Maternai ID	Male	Male Female	Male (%)	Fetal	Male	Female	Fetal	Маје	Female
84F238	9	m	67	+1	+1		93 ± 4		+1
84F246	4	S	44	+1	43 ± 2	43 ± 7	100 ± 5	e + 66	1 -
84F251	H	က	25	46 ± 2	44		95 ± 7	66	8 +1 :5
84F258	5	٣	63	+1	40 ± 5	41 ± 6	98 ± 3	+i	
84F260	11	7	8.5	+1	+(+!		86 ± 5	Ž.

, rearonemented as	Estatistic volumente en	AND A STREET WAY	*****	*******	legingett.
		[ត់	θ	۷۳ ۱۱
0			Mean Length (mm) ± 3.5.	Female	20
S R			(mm)	به	7 +1
<u> </u>		als	ength	Male	693
		Anim	ean I	1	ε .
		Fetal Sex, Weight, and Length - 25 mg/kg/day Fydroxyurea Animals	Σ	Fetal	93 ±
		drox			
100		lay Fy		.1e	4
		/kg/d	Weignt (g) I 3.D.	Female	35 + 4
		25 mg	£ (ģ)		4
		ا با	ignt	Male	35 ± 4
222		Leng			च
o c		and	Mean	Fetal	#1 #3 #5
20		ight,		[
g.a.		K, We		(10)	•
دده		al Se:		Male (%)	55
		Fet		Female N	
			Sex	Fema	5
e G				Male	9
53.					44.
AND ODGGGGAN BANANAN BURNANAN MANANAN MANANANAN				Maternal ID	84F2.16
			I	Σ	1
	APPINDIX	G - 2			

Fetal Sex, Weight, and Length - 50 mg/kg/day Hydroxyurea Animals

Consideration of the contract of the contract

± S.D.	Female	99 ± 4 99 ± 3 92 ± 6
Mean Length (mm) ± S.D.	Male	102 ± 4 94 ± 9 95 ± 3
Mean L	Fetal	100 ± 4 98 ± 5 94 ± 5
s.D.	Female	44 + 3 44 + 5 36 + 4
Mean Weight (g) ± S.D.	Male	45 ± 3 41 ±11 35 ± 4
меап м	Fetal	44 43 44 44 44 44
	Male (%)	25 22 56
Sex	1 1	9 L 4
	Male Female	01 01 W
	Maternal ID	84F244 84F253 84F261

Fetal Sex, Weight, and Length - 150 mg/kg/day Hydroxyurea Animals

		зек		na ex	Mean Weight (g) ± 5.D.	+ S.D.	Mean	Mean Length (mm) t 3.D.	+ 3.D.
Maternal ID	π ala a	Female	Male (%)	म स्कर्	Маје	Female	Fotal	Male	क एक स्थान
00 00 00 00 00 00 00 00 00 00 00 00 00	0 10 00	មេខក	00000 55000	ന വനന ഇടി (14) സം (20) സം (20)	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	33 33 43 43 43 43 43 43 43 43 43 43 43 4	20.00 t t t t t t t t t t t t t t t t t t	98 90 4 41 41 41 41 41 41 41 41 41 41 41 41 41 4	(* 14 (*) 41 (*) (*) (*) (*) (*) (*) (*) (*)

Fetal Sex, Weight, and Length - 200 mg/kg/day Hydroxyurea Animals

± S.D.	Female	91 ± 3 94 ± 3
Mean Length (mm) ± S.D.	Male	4 + + + + + + + + + + + + + + + + + + +
Mean L	Fetal	93 ± 4 91 ± 4
s.D.	Female	35 ± 4 35 ± 2
Mean Weight (g) ± S.D.	Male	35 ± 4 33 ± 6
Mean W	Fetal	35 ± 4 34 ± 4
	Male Female Male (%)	62.
Sex	Female	(% (B)
	Male	۸) 4,
	Maternal ID	84F250 84F254

Fetal External Examination - Control Animals

			Variants		Malformations
ω †∵,	* 0 Z	 +- 0 Z	No. and Description of Each Variant	No. ô	No. and Description of Each Malformation
(1 (1 (1 (1 (1 (1 (1 (1	c,	0		0	
17 (V 11) (T)	W	O		0	
1772478	s.gr	0		0	
1 2 7 9	30	0		0	
7.7.1.1.2	.~^ •−1	0		0	

*Number of fetuses examined. *Number of fetuses with variants. \$Number of fetuses with malformations.

Fetal External Examination - 25 mg/kg/day Hydroxyurea Animals

			Varjants	Maltormations
Maternal ID	Mo.*	No.	No. and Description of Each Variant	No.S No. and Description of Each Malformation
34E255	l 	0		0
*Number of SNumber of	1674Ses 1674Ses 1 fetuses	- 80 × 8 × 8 × 8 × 8 × 8 × 8 × 8 × 8 × 8	nted Variants.	

Fetal External Examination - 50 mg/kg/day Hydroxyurea Animals

us	ption	9			
Malformations	No. and Description of Each Malformation				
	No.\$	0	0	0	
Variants	No. and Description of Each Variant				
	No. +	0	0	0	
	*.	30	n	Ø)	4
	Maternal ID	84F244	84F253	84F261	

*Number of fetuses examined.
**Number of fetuses with variants.
**SNumber of fetuses with malformations.

Fetal External Examination - 150 mg/kg/day Hydroxyurea Animals

Malformations	No. and Description of Each Malformation		l Hyperflexed forepaw			
	No.S	()		0	0	
Variants	No. and Description of Each Variant					The state of the s
	No.	0	0	0	0	
	, 0 Z	0 1	16	0	ω	
	Maternal	84E255	847239	84F263	84E267	

*Number of fetuses examinad. #Number of fetuses with variants. \$Number of fetuses with a librations

Fetal External Examination - 200 mg/kg/day Hydroxyurea Animals

spazai Presezzaki Viktorkaj Presezaki Presezaka (Presezaki Benesaka Benesaka Benesaka Benesaki Benesaki Benesak K

			Variants		Malformations
Maternāl ID	%.	No. * No. †	No. and Description of Each Variant	No. §	No. and Description of Each Malformation
84F25C	_ ∞		1 Body dark red	2	2 Curly tail
84F254	۲۰	0		П	1 Tongue malformed

*Number of fetuses examined. TNumber of fetuses with variants. SNumber of fetuses with malformations.

Fetal Visceral Examination - Control Animals

Malformations	No. and Description of Each Malformation					
	No.S	0	0	0	0	0
Variants	No. and Description of Each Variant		1 Nasal concha underdeveloped	<pre>1 Cerebrum underdeveloped, right hemisphere</pre>		<pre>1 Lateral ventricle dilated</pre>
	No.†	0	г	₩	9	2
	%.	5	4	8	7	(Q)
	Maternal ID	84F238	84F246	84F251	84F258	84F260

*Number of fetuses examined.

*Number of fetuses with variants.

\$\text{SNumber of fetuses with malformations.}\$

Malformations	No. and Description of Each Malformation		
	No.6%	0	
Variants	No. and Description of Each Variant	<pre>Lateral ventricle dilated Larachnoid space dilated Heart left ventricle Slightly enlarged LGall bladder smail Kidneys small</pre>	mined. h variants. C malformations.
	+ 0 2	4	ses examir ses with t
	*. o Z	(C)	######################################
	Maternal ID	84F266	*Number of †Number of §Number 3

50 mg/kg/day Hydroxyurea Animals Fetal Visceral Examination

Malformations	No. and Description of Each Malformation		Heart left atria underdeveloped, marked	Kidney ectopic	
	N O H		Η,	- 1	
	No. S	0	2	0	
Variants	No. and Description of Each Variant	Ovary short/thickened	Kidney lobular	i Lateral ventricles dilated	
	0 Z C		1		
	No. * . CN	-	r~4	7	
	* O Z	4	۲,	*- : *	
	Maternal ID	84F244	84F253	84F261	

KALAN SISISISIN MISHAW DIBIKAL SISISISIN KAKATUT KASISISI PERISIAN BANDIN T**PERISI** D**IDI**DIR BISS

Fetal Visceral Examination - 150 mg/kg/day Hydroxyurea Animals

POCOCIA REPORTANTA DE LA COCICA DEL COCICA DE LA COCICA DEL COCICA DE LA COCICA DEL COCICA DE LA COCICA DEL COCICA DEL COCICA DE LA COC

TO DESCRIPTION OF THE PROPERTY OF THE PROPERTY

4F263 4 4	Variants	,		Malformations
45259 4 2 2 2 4 4 2 2 4 4 4 5 5 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9			No.S	No. and Description of Each Malformation
4F2559 5 0 4F263 4 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	ļ ļ	nderdeveloped Lickened	H	1 Heart right atria underdeveloped, marked
4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5			Н	1 Esophagus <mark>situs</mark> inversus
		inderdeveloped cie dilated n dilated small	0	
			C	

*Number of fetuses earning.d.
| Number of fetuses with variable.
| Snumber of fetuses with reformations.

.

HANNEY HANNEYS LANDONE

PROCEELS !

2522523 255555

28.22.23

3 2 2 Nasal concha underdeveloped 2 1 Renal pelvis dilated	
4 2 l Nasal concha underdeveloped l 2 Heart atria small	1 Stomach situs inversus
No.* No.† No. and Description No.5 of Each Variant	No.\$ No. and Description of Each Malformation
Variants	Malformations
Fetal Vi.ceral Examination - 200 mg/kg/day Hyo	200 mg/kg/day Hydroxyurea Animals

with variants. with malformations. fetuses examined. fetuses fetuses *Number of thumber of Shumber of +Number

2555555 JACCESSE

				Variants		Maltormations
™ a t	Maternal ID	, OZ	t 0N	No. and Description of Each Variant	No.%	No. and Description of Each Malformation
845	238	(L)	જ	4 13 pairs of ribs 1 Unilateral rudimentary 13th rib 1 Scapula spine crooked	0	
8 4 F	246	IL)	۲	4 13 pairs of ribs 1 Short 13th rib 1 Unilateral ruaimentary 13th rib	rd	1 Rudimentary cervical rib
数 は に	251	~	2	2 13 pairs of ribs 1 Short 13th rib	0	
8 4 5	258	4	4	4 13 pairs of ribs	0	
ω 57 14	(ع س ري	(-	ø	4 13 pairs of ribs 2 Unilateral rudimentary 13th rib 2 Sternebrae split/unilate ossification	0 eral	

Feral Skeleral Examination - 25 mg/kg/day Hydroxyurea Animals

Maiformations	No. and Description of Each Malformation	
	No.s	O
Variants	No. and Description of Each Variant	5 13 pairs of ribs 1 Short 13th rib
	% +	W)
	* 0 2	·Ω
	G C C C C C C C C C C C C C C C C C C C	10 10 14 14 57 00

*Number of fetuses examined. *Number of fetuses with variants. \$Number of fetuses with molformations. T SSSSSS TECCSSSS TECCSSSS TECCSSSS TECCSSSS TECCSSSS TECCSSSS TECCSSSS TECCSSSS TECESSORT DESCRIPTION

50 mg/kg/day Hydroxyurea Asimals Fetal Skeletal Examination -

			Variants	Malformations
Maternal ID	*. O.Z.	0 Z	No. and Description of Each Variant	No.\$ No. and Description of Each Malformation
8 45 Z E 78	7	4	4 13 pairs of ribs	0
ش ال) (ط البر البر ش	S	'n	5 13 pairs of ribs	0
845261	S	5	5 13 pairs of ribs	0

*Number of fetuses examined.
*Number of fetuses with variants.
\$\text{Simber of fetuses with malformations.}

Posal Skeletal Examination - 150 mm/kg/day Hydroxyurea Animals

				Variants		•	Malformations
Mercerral (a)	*. 0 Z	07	0 to 20 to	and Deserrach Varia	\$ 000 \$ 000	. ii 20	and Descr ach Malfo
847255	م		i market di	13 pairs of ribs Snort 1st rib Frontal/parietal suture jagged SterneGrae split or unilateral ossification		ಣ ಇ	
(5) (6) (8) (8) (8) (8)	٠n	(<)	F4 - 1 (V) 1	Scapula spine crooked Sterrebrae fused Sternebrae scrambled Sternebrae split (t unilateral ossification	ιζ	ଅଫ କ	14 Pairs of ribs 20 Thoracic + lumbar vertebrae 21 Thoracic + lumbar vertebrae
11E263	ເລ	<i>ና</i> ግ	Book of the	it pairs of ribs Lierneniae fused Sacral Terrebral aich wide	tr')	ഗ ത	8 Cervical verrebrae 20 Thoracia + Lumbar vertebras
34E267	ď	e (e · · · ·	Short 'st "ib Steirebrae split or sailut (a) oskifioation	(*)	6 5) 177	is Polis of Class 20 The Prise + Lumbar 21 The Prise + Lumbar

Mumber of fetuses examined. Mumber of fetuses with purishes Synther of fetuses with surformations PRINCES STREET, STREET, SALVING PRINCES BETTER

77777

Becen selecte recommend medices record named in all and a selected records as the second of a selected records

rib

with malformations. ter with variants. (数数分割数数数数数数数数数数数

The state of the Examination From From Animals

	8 11 10 11	100 100 100 100
	N	രു ന വ എ ഗ
tal	rmed	20000
Cxeletal	walfo No.	0 0 0 0 0
	Number Wilformed Variants Exambned No. % No. %	თ თ :4 ლ (
	ants.	00000
:	21 - 1 at 7 > 24	62.4.6
	ការខេត្ត	our contra
V: 506.141	Mass for	ବ୍ଦେଶ
	Number Mulformed Variants Examined No. 1 2.1	च पाटा मार
	S C	ರಾ ୧୯ ଓ ୧୯
	74 75 77 74	00000
	S TO STATE OF THE	Crack Const
) }	C CO CD C
		त्र त्राच्या का उ
	: ::::::::::::::::::::::::::::::::::::	

25 mg/kg/dny Hydronyevea Animals or Total Examination Findings .

SECURIOR SECURIOR DEFINED DESCRIPTION OF SECURITION OF SECURITION OF SECURITION OF SECURITION OF SECURITIONS OF SECURITIES

	ធាំ	1 1 4 4 1 H				Visceral	ral				ckeletal	رة د ا		
	ì			:			1				1	!		
ex of the second	Number Ma Examined N	Mairinged Carlants No. No. %	r vari	ري د اوس د اوس	Number Malfinsed Variants Examined No. 1 No.	Ma ∫ € No.		Varia No.	1) 42 53 t	Number Maltormed Virlants Examined No. 1 No. 1	Malto No.	the d	Vari	ant:
		i		1		1	İ		1				1	
	•	0 0	C	0	^	0	ب	4	0 6 4 80	9	O	0 5 84	ภ	5 0


i	20 m	100
:	Va: No.	ਰਾ ਹੀ ਹੀ
ं हु	rined Val	000
- Xivetal	Molformed Variants	000
		e or
	in the state of th	an en
	1 4 1	
-		2 0 7
20 20 40 50		0 (4 a)
	20 m	् एक्ट
		ချစ်လ
		3 O S
		O C.
:		000
		¥1.3 .
	at 1	The second secon

BOOK BREEK, BEEKK BEEKK BEEKK BEEKK BEEKK BEEKKE BEEKKE BEEKKE BEEKKE BE

Incidence of Fetal Examination Findings - 150 mg/kg/day Hydroxyurea Animals

PRODUCTION CONTRACT CONTRACT CONTRACT CONTRACT CONTRACTOR

	ι; _{υν} , τ	
	Vari. No.	တ္ကတ္ ျ
etal	rmed %	50 100 100
Skeletal	Malfo No.	സവന
	Number Malformed Variants Examined No. % No.	ოიად
	ants ®	50 100 0
	Vari No.	7040
191	zred š	8 0 8 0 0 0
Visceral	daifo No.	H H O O
	Number Maiforned Variants Examined No. 8 No. 8	みいみ の
	ants %	0000
	Varian Nc. %	2000
- -	0 1	0000
Externa	Maifried Variants	• • •
	Number Franched	50 m W
		89 48 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6



Coppes et al--88

OFFICIAL DISTRIBUTION : IST

Commander US Army Medical Research & Development Command

ATTN: SGRD-RMS/Mrs. Madigan Fort Detrick, MD 21701-5012

Defense Technical Information Center ATTN: DTIC/DDAB (2 copies) Cameron Station Alexandria, VA 22304-6145

Office of Under Secretary of Defense Research and Engineering ATTN: R&AT (E&LS), Room 3D129 The Pentagon Washington, DC 29301-3080

DASG-AAFJML

Army/Air Force Joint Medical Library Offices of the Surgeons General 1109 Leesburg Pike, Room 670 Falls Church, VA 22041-3258

HO DA (DASG-ZXA) WASH DC 20310-2300

Commandant Academy of Health Sciences US Army ATTN: HSHA-CDM Fort Sam Houston, TX 78234-6100

Uniformed Services University of Health Sciences Office of Grants Management 4361 Jones Bridge Road Bethesda, MD 20814-4799

US Army Research Office ATTN: Chemical and Biological Sciences Division O Box 12211 Per earch Triangle Park, NC 27709-2211

director ATTN: SGRD-UWZ-L Walter Reed Army Institute of Research Washington, DC: 20:07-5100

Fommander IS Army Medical Research Institute of Infectious Diseases ATTN: SGRD-ULZ-A ort Detrick MD 21701-5011

ommander 'S Army Medical Bioengineering Research nd Ucyclopment Laboratory JTTN: SGRD-UBG-M err Detrick, Bldg 568 referick, MD 21701 5010

Commander US Army Medical Processing Research & Development Tabore of ATTN: Library Fort Detrick, Bldg of & Frederick, MD 2170. 1000

Commander US Army Research institute of Environmental Medicina ATTH: SGRD-UE-KSA Kansas Street Natick, MA 01780-5007

Communiter US Army Pescerch Product of Surgical Research Fort Sam Houston, TX 7323- (100)

Comman fer US Army Research Institute of Chemical Defense ATTN: SGRE-UV-AJ Aberdeen Proving Groad Sett 21018 235

Commander. US Army Acromodical Ruseart: Laboratory Fort Rucker, AL 35 to 5006

AIR FORCE Office of Scientific Research (NL) Building 410, Room A21/ Boiling Air Force Base, DC 17832 1/48

USAN School of Actospace Modernia Document 5 stion USAFCAN/TSKD Brooms Air Force mase, Transport 5274 5771

Head, Biologic & Sciences, Division OFFICE OF NAVAUR ISBARCH 800 North Queeny Survey Arlington, VA 2227 - 567

Compander Naval Medical Commission (2) Department of the No. Washingma, OC 20372 51 10